Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood
Key result
Enteric-coated aspirin matches regular aspirin in inhibiting platelet aggregation and suppressing thromboxane A2 production.
- n=33
Why the study?
Enteric-coated aspirin preparations were tested as possible alternatives to regular aspirin for platelet inhibition due to reports of gastric irritation among low-dose aspirin users.
Does alternate-day enteric-coated aspirin inhibit platelet aggregation, prolong bleeding time, and suppress thromboxane A2 levels as effectively as regular aspirin in volunteers?
Comparison
Regular aspirin (325 mg) vs two enteric-coated aspirin preparations (325 mg) vs placebo
Design
Randomized assignment to four treatment groups
Follow-up
After seven alternate-day doses
Authors
Discussion
Loading...
Member takes
Implication
May permit enteric-coated aspirin in gastric-intolerant patients; reinforces every-other-day dosing for platelet inhibition.
Study Design
Type
RCT (n=33)
Randomization
Randomly assigned
Structured PICO
Does alternate-day enteric-coated aspirin inhibit platelet aggregation, prolong bleeding time, and suppress thromboxane A2 levels as effectively as regular aspirin in volunteers?
P
Population
33 volunteers assigned to regular aspirin, enteric-coated aspirin, or placebo every other day for seven doses.
I
Intervention
Two enteric-coated aspirin preparations (325 mg) administered every other day for seven doses
C
Comparator
Regular aspirin (325 mg) every other day, and placebo
O
Outcome
Bleeding times, platelet aggregation, and thromboxane A2 levels (in vitro and in collected bleeding-time blood) measured before and after a single dose and after seven alternate-day dosessurrogate
Enteric-coated aspirin is as effective as regular aspirin in inhibiting platelet activity when administered every other day, offering a potential alternative for patients with gastric irritation.
Cite This Study
Stampfer et al. (1986) reported an RCT. Enteric-coated aspirin vs. Regular aspirin and placebo was evaluated on Bleeding times, platelet aggregation, and thromboxane A2 levels. Enteric-coated and regular aspirin (325 mg every other day) were equally efficacious in prolonging bleeding time, inhibiting platelet aggregation, and suppressing thromboxane A2 production (>99%).